Title: Statin Use and the Risk of Hepatocellular Carcinoma Among Patients With Chronic
Hepatitis B: An Emulated Target Trial Using Longitudinal Nationwide Population Cohort Data
Version: 1 Date: 07 Aug 2023
Reviewer's report:
1. The risk of hepatocellular carcinoma can be directly related to the degree of cirrhosis.
However, the percentage of cirrhosis and the severity of liver disease cannot be clarified among
the two groups.
2. A recent original article "Association of statin use with risk of liver disease, hepatocellular
carcinoma, and liver-related mortality" had been published on Gastroenterology and hepatology
2023 June 26 by Mara Sophie Vell et.al. Can the authors point the differences between the two
articles?
3. The authors concluded that statin might have a benefit for preventing HCC in CHB patients
with elevated cholesterol levels. However, further investigations should be done to clarify (1) if
more potent statins (i.e. rosuvastatin and atorvastatin) is recommmeded for chemo-prevention;
(2) the recommended cut-off value of cholesterol for chemo-prevention.
Title: Statin Use and the Risk of Hepatocellular Carcinoma Among Patients With Chronic
Hepatitis B: An Emulated Target Trial Using Longitudinal Nationwide Population Cohort Data
Version: 1 Date: 07 Aug 2023
Reviewer's report:
1. The risk of hepatocellular carcinoma can be directly related to the degree of cirrhosis.
However, the percentage of cirrhosis and the severity of liver disease cannot be clarified among
the two groups.
2. A recent original article "Association of statin use with risk of liver disease, hepatocellular
carcinoma, and liver-related mortality" had been published on Gastroenterology and hepatology
2023 June 26 by Mara Sophie Vell et.al. Can the authors point the differences between the two
articles?
3. The authors concluded that statin might have a benefit for preventing HCC in CHB patients
with elevated cholesterol levels. However, further investigations should be done to clarify (1) if
more potent statins (i.e. rosuvastatin and atorvastatin) is recommmeded for chemo-prevention;
(2) the recommended cut-off value of cholesterol for chemo-prevention.
Please review this paper.
user
Title: Statin Use and the Risk of Hepatocellular Carcinoma Among Patients With Chronic
Hepatitis B: An Emulated Target Trial Using Longitudinal Nationwide Population Cohort Data
Version: 1 Date: 07 Aug 2023
Reviewer's report:
1. The risk of hepatocellular carcinoma can be directly related to the degree of cirrhosis.
However, the percentage of cirrhosis and the severity of liver disease cannot be clarified among
the two groups.
2. A recent original article "Association of statin use with risk of liver disease, hepatocellular
carcinoma, and liver-related mortality" had been published on Gastroenterology and hepatology
2023 June 26 by Mara Sophie Vell et.al. Can the authors point the differences between the two
articles?
3. The authors concluded that statin might have a benefit for preventing HCC in CHB patients
with elevated cholesterol levels. However, further investigations should be done to clarify (1) if
more potent statins (i.e. rosuvastatin and atorvastatin) is recommmeded for chemo-prevention;
(2) the recommended cut-off value of cholesterol for chemo-prevention.
assistant